8-K: Accolade Reports Strong First Quarter Results, Revenue Up 18%

Accolade, Inc. announced its fiscal first quarter 2025 results, showing an 18% increase in revenue and significant improvement in adjusted EBITDA.

Summary

• Accolade, Inc. reported its financial results for the first fiscal quarter ended May 31, 2024.
• The company's revenue increased by 18% year-over-year, reaching $110.5 million compared to $93.2 million in the same quarter last year.
• Net loss improved by 28%, decreasing to $27.6 million from $38.4 million year-over-year.
• Adjusted EBITDA showed a significant improvement, with a loss of $3.3 million compared to a loss of $12.6 million in the prior year, a 73% improvement.
• Adjusted gross profit increased by 30% to $52.8 million, up from $40.6 million.
• The adjusted gross margin also improved to 47.8% from 43.5%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, significant improvement in adjusted EBITDA, and a reduction in net loss. The company's focus on profitable growth and positive adjusted EBITDA this year is encouraging. However, the company is still reporting a loss, which prevents a higher score.

Positives

• Accolade demonstrated strong revenue growth of 18% year-over-year.
• The company significantly reduced its net loss by 28%.
• There was a substantial improvement in adjusted EBITDA, with a 73% reduction in losses.
• Adjusted gross profit and margin both showed significant improvements, indicating better operational efficiency.
• The company is focused on delivering profitable growth and positive adjusted EBITDA this year.

Negatives

• Accolade still reported a net loss of $27.6 million for the quarter.
• The company is still reporting a loss in adjusted EBITDA, although it is significantly reduced.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Accolade has not reconciled guidance for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and has not provided forward-looking guidance for net loss, because there are items that may impact net loss, including stock-based compensation, that are not within the company's control or cannot be reasonably predicted.

Future Outlook

Accolade expects revenue between $104 million and $106 million and an adjusted EBITDA loss between $8 million and $10 million for the fiscal second quarter ending August 31, 2024. For the fiscal year ending February 28, 2025, they expect revenue between $460 million and $475 million and adjusted EBITDA between $15 million and $20 million.

Management Comments

• Rajeev Singh, Accolade Chairman of the Board of Directors and Chief Executive Officer, stated that the company's physician-led advocacy approach is increasing accessibility to healthcare and improving outcomes.
• Rajeev Singh also mentioned that they will continue to push their leadership in Healthcare AI and a proven engagement model that is driving sustainable and profitable growth.
• Steve Barnes, Accolade Chief Financial Officer, commented that Accolade continues to execute against their primary objective of delivering profitable growth and positive Adjusted EBITDA this year.
• Steve Barnes also stated that they are de-risking their full year revenue forecast and focusing investments on margin expansion and revenue opportunities that support their profitability objectives.

Industry Context

Accolade's focus on personalized healthcare, virtual primary care, and mental health aligns with the growing trend of digital health solutions and the increasing demand for accessible and convenient healthcare services. The company's emphasis on AI and care navigation also reflects the industry's move towards leveraging technology to improve patient outcomes and reduce costs.

Comparison to Industry Standards

• Accolade's revenue growth of 18% is strong compared to some established players in the healthcare technology space, but it is important to compare this to companies with similar business models and growth stages.
• Companies like Teladoc Health and Livongo (now part of Teladoc) have seen varying growth rates, and Accolade's performance should be benchmarked against these and other similar companies.
• The improvement in adjusted EBITDA is a positive sign, as many healthcare technology companies struggle with profitability in their early stages.
• Accolade's adjusted gross margin of 47.8% is a key metric to watch, as it indicates the efficiency of their service delivery and pricing strategy. This should be compared to industry benchmarks for similar healthcare services.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved profitability metrics positively.
• Employees may be encouraged by the company's focus on growth and profitability.
• Customers may benefit from the company's continued investment in improving healthcare experiences.
• Suppliers and creditors may see the company as a more stable and reliable partner due to its improved financial performance.

Next Steps

• The company will host a conference call on June 27, 2024, to discuss the financial results.
• Accolade will continue to focus on delivering profitable growth and positive adjusted EBITDA.
• The company will focus investments on margin expansion and revenue opportunities that support profitability objectives.

Key Dates

Keywords

Healthcare, Personalized Healthcare, Financial Results, Revenue Growth, Adjusted EBITDA, Gross Profit, Healthcare AI, Care Navigation, Virtual Primary Care, Mental Health